Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation

Veno-occlusive Disease Clinical Trial

Official title:

Defibrotide for Hematopoietic Stem Cell Transplant Patients With Severe Hepatic Venocclusive Disease: A Phase I/II Study to Determine the Minimal Effective Dose

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00003966
• Other study ID #: 99118
• Secondary ID: P30CA015704DFCI-
• Status: Completed
• Phase: Phase 2
• First received: November 1, 1999
• Last updated: January 19, 2017
• Start date: April 2000
• Est. completion date: April 2006

Study information

• Verified date: January 2017
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Giving defibrotide may be an effective treatment for liver damage that may result following peripheral stem cell transplantation.

PURPOSE: This randomized phase II trial is studying defibrotide to see how well it works in treating patients with severe liver disease after undergoing peripheral stem cell transplantation.

Description:

OBJECTIVES:

• Determine complete response rate in post-hematopoietic stem cell transplant patients with severe veno-occlusive disease of the liver treated with defibrotide.

• Determine the minimal effective dose of this drug in these patients.

• Assess toxicity and adverse side effects of this drug in these patients.

OUTLINE: This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.

• Arm I: On days 2-14, patients receive a lower dose of defibrotide IV over 2 hours every 6 hours.

• Arm II: On days 2-14, patients receive a higher dose of defibrotide IV over 2 hours every 6 hours.

In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 140 patients (70 per treatment arm) will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 151
• Est. completion date: April 2006
• Est. primary completion date: February 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria

• Clinical diagnosis of VOD defined by:

• Jaundice (bilirubin = 2 mg/dL) and 2 or more of the following: ascites, weight gain > 5% above baseline weight (see Section 5.2), hepatomegaly, RUQ pain

• Patients with jaundice and reversal of flow on Doppler examination of the portal vein will be eligible with one of the following: ascites, weight gain > 5% above baseline weight, hepatomegaly, RUQ pain

• Patients with pre-existing hepatomegaly must have documentation by physical exam or imaging that liver size is increased over baseline at admission

• Patients who do not meet the criteria in Section 3.1.1 (ie. have two of the major criteria but not three) and have biopsy proven VOD are eligible in the presence of characteristics consistent with severe disease (see below).

• Patients with concurrent, confounding causes of liver dysfunction clinically evident or evident on ultrasound or other radiographic imaging (such as evidence of biliary ductal dilatation or focal tissue defects) may require biopsy-proven VOD and/or elevated wedged trans-hepatic venous pressure gradient measurement ( =10 mm mercury) to be considered eligible. Best medical judgment and further imaging studies can be used to clarify the diagnosis and determine confounding causes of liver dysfunction.

• Severity of VOD defined by:

• For patients addressed by the Bearman model (i.e. within 16 days of SCT and conditioned with either BU/CY, CY/TBI or CBV), there must be a 30% or greater risk of severe VOD (see Appendix B).

• For all other patients who are not addressed by the Bearman model (ie. beyond 16 days of SCT and/or not conditioned with either BU/CY,

• CY/TBI or CBV), there must be concomitant multi-organ failure defined as presence of one or more of the following :

• renal dysfunction: a) creatinine =2x value on the date of admission day to the BMT unit for conditioning or =2x lowest value during conditioning (use the lowest value for calculation), or b) creatinine clearance or GFR =50% of admission value, or c) dialysis dependence"

• pulmonary dysfunction: documentation of oxygenation saturation = 90% on room air; requirement for positive pressure/ventilator dependence

----pulmonary dysfunction must not be attributable to another cause (e.g. documented infectious pneumonia)

• central nervous dysfunction: documentation of confusion, lethargy, and/or delirium ---- central nervous dysfunction must not be attributable to another cause (e.g. documented cyclosporin toxicity)

• Patients or their parents/guardians or designated proxy must have the ability to give voluntary informed consent to the protocol. Where possible, patient assent will also be obtained

• Patients must be = 12 hours after cessation of heparin

• Patient must have an eligible diagnosis of VOD by Day 35 post transplant

• Exclusion Criteria

• Patients receiving concomitant heparin or other anticoagulants unless being used for routine CVL management, fibrinolytic instillation for CVL occlusion, intermittent dialysis or ultrafiltration are excluded. Patients who have received systemic t-PA (concomitant or prior) are excluded.

• Patients with significant uncontrolled acute bleeding, defined as hemorrhage requiring > 15 cc/kg of packed red blood cells (ie. a pediatric patient weighing 20 kg and requiring > 300cc of packed red blood cells /24 hours or an adult patient weighing 70 kg and requiring >3 units of packed red blood cells/24 hours) to replace blood loss are excluded. These parameters must be reviewed prior to enrollment by the PI or his/her designate.

• Patients with hemodynamic instability as defined below:

• Hemodynamic stability is defined as having no requirement for pressor support OR being able to maintain mean arterial pressure within 1 SD of age-adjusted levels with pressor support (see Appendix D)

• Patients requiring renal dose dopamine alone (2-5 mcg/kg/min) are eligible without measurement of mean arterial pressure

• Patients with Grade B-D GVHD, graded according to the IBMTR Severity Index (see Appendix G). Please note patients with Grade B skin only are eligible.

• Patients intubated for documented intrinsic lung disease

--- Patients intubated secondary to a mechanical barrier to ventilation, e.g.pulmonary edema or ascites, will be eligible as long as the PaO2/FiO2 ratio is = 300 and/or the oxygen index (OI={MAP x FiO2}÷ PaO2 x 100) is = 25% at the time of enrollment

• Patients who meet Grade IV common toxicity criteria for neurotoxicity (other than Grade IV confusion and/or delirium), i.e. coma, seizures, toxic psychosis

• Patients who are currently receiving treatment with another experimental agent.

• Please note that an experimental agent in this setting is defined as any drug or device used under an IND designation which is associated with systemic effects that could influence the outcome in a patient with severe VOD. If the continued use of an experimental agent is considered both necessary and appropriate, this must be reviewed and approved on a case by case basis by the Overall Study PI, Dr. Paul Richardson, or his designate, who will approve the entry of patients being concurrently treated with another experimental agent only if there is no evidence for a potential adverse pharmacokinetic interaction or overlapping toxicity.

Related Conditions & MeSH terms

• Veno-occlusive Disease

Intervention

Drug:
• defibrotide

Locations

Country	Name	City	State
United States	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Children's Hospital Boston	Boston	Massachusetts
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	City of Hope Comprehensive Cancer Center	Duarte	California
United States	Duke Comprehensive Cancer Center	Durham	North Carolina
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	Fred Hutchinson Cancer Research Center	Seattle	Washington

Sponsors (3)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Jazz Pharmaceuticals, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Richardson P, Soiffer RJ, Antin JH, et al.: Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): results of a phase II, multicenter, randomized stu

Richardson PG, Soiffer R, Antin JH, et al.: Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT). [

Richardson PG, Soiffer RJ, Antin JH, et al.: Defibrotide (DF) for the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post SCT: final results of a phase II, multicenter, randomized study and preliminary analyses of su

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response Rate as measured by a total bilirubin of < 2 mg/dL and resolution of multi-organ failure attributable to veno-occlusive disease (VOD)		60 Days
Secondary	Survival at 100 days following stem cell transplantation		100 days following stem cell transplantation
Secondary	Toxicity by NCI Common Toxicity Criteria version 2.0 during study and 30 days after study completion		during study and 30 Days after study completion
Secondary	Grade 3-4 end organ dysfunction attributable to defibrotide as determined by NCI Common Toxicity Criteria version 2.0 during study and 30 days after study completion		during study and 30 Days after study completion
Secondary	Occurrence of other adverse events by NCI Common Toxicity Criteria version 2.0 during study and 30 days after study completion		during study and 30 Days after study completion
Secondary	Effect of drug on plasminogen activator inhibitor-1 (PAI-1) determination of dose-relationship between drug and/or VOD response as measured by survival, PAI-1 levels, and research assays at day 100		100 Days
Secondary	Feasibility of pharmacokinetics (PK) across dose arms and the PK of defibrotide by PK analysis